Cargando…

Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes

The quantity of programmed cell death-ligand 1 (PD-L1) is regarded as a predicting factor of clinical response to anti-PD-1 axis immunotherapy. However, the expression of PD-L1 and its prognostic value in hepatocellular carcinoma (HCC) patients remain debated. Meanwhile, the molecular features of PD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liao, Haotian, Chen, Wen, Dai, Yunlu, Richardson, Joseph J., Guo, Junling, Yuan, Kefei, Zeng, Yong, Xie, Kunlin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749030/ https://www.ncbi.nlm.nih.gov/pubmed/31572677 http://dx.doi.org/10.3389/fonc.2019.00883

Ejemplares similares

Immune-Related Biomarkers Improve Performance of Risk Prediction Models for Survival in Patients With Hepatocellular Carcinoma
por: Wan, Haifeng, et al.
Publicado: (2022)

Improving the synergistic combination of programmed death‐1/programmed death ligand‐1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment
por: Mudassar, Faiqa, et al.
Publicado: (2022)

The Efficacy and Safety of Programmed Death-1 and Programmed Death Ligand 1 Inhibitors for the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
por: He, Shukang, et al.
Publicado: (2021)

Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma
por: Liu, Chao-Qun, et al.
Publicado: (2018)

The predictive role of soluble programmed death ligand 1 in digestive system cancers
por: Ruan, Jian, et al.
Publicado: (2023)

Expression, correlation, and prognostic significance of different nicotinic acetylcholine receptors, programed death ligand 1, and dopamine receptor D2 in lung adenocarcinoma
por: Pal, Krishnendu, et al.
Publicado: (2022)

Expression of Human Epidermal Growth Factor Receptor-2 Status and Programmed Cell Death Protein-1 Ligand Is Associated With Prognosis in Gastric Cancer
por: Lv, Huifang, et al.
Publicado: (2021)

Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis
por: Zhang, Chen, et al.
Publicado: (2021)

Corrigendum: Expression of Human Epidermal Growth Factor Receptor-2 Status and Programmed Cell Death Protein-1 Ligand Is Associated With Prognosis in Gastric Cancer
por: Lv, Huifang, et al.
Publicado: (2021)

Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
por: Iafolla, Marco A. J., et al.
Publicado: (2017)

Programmed cell death‐ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics
por: Mou, Haibo, et al.
Publicado: (2021)

Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers
por: Maughan, Benjamin L., et al.
Publicado: (2017)

Correlation Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Programmed Death-Ligand 1 Expression as Prognostic Markers in Non-Small Cell Lung Cancer
por: Pirlog, Cristina-Florina, et al.
Publicado: (2022)

The Prognostic Value of Programmed Death-Ligand 1 in a Chinese Cohort With Clear Cell Renal Cell Carcinoma
por: Xiao, Wen-jun, et al.
Publicado: (2019)

The Epigenetic Regulation of Microenvironment in Hepatocellular Carcinoma
por: Wang, Fang, et al.
Publicado: (2021)

A novel machine learning-based programmed cell death-related clinical diagnostic and prognostic model associated with immune infiltration in endometrial cancer
por: Xiong, Jian, et al.
Publicado: (2023)

Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors
por: Song, Joon Seon, et al.
Publicado: (2019)

The Prognostic Value of Circulating Soluble Programmed Death Ligand-1 in Cancers: A Meta-Analysis
por: Huang, Pei, et al.
Publicado: (2021)

Prognostic Value of Galectin-9 Relates to Programmed Death-Ligand 1 in Patients With Multiple Myeloma
por: Lee, Byung-Hyun, et al.
Publicado: (2021)

Correlation Patterns Among B7 Family Ligands and Tryptophan Degrading Enzymes in Hepatocellular Carcinoma
por: Chinnadurai, Raghavan, et al.
Publicado: (2020)

Prognostic Role of Soluble Programmed Death Ligand 1 in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Liao, Guixiang, et al.
Publicado: (2021)

Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials
por: Zeng, Linyan, et al.
Publicado: (2022)

Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers
por: Mouri, Atsuto, et al.
Publicado: (2021)

Correlation between fibroblast growth factor receptor mutation, programmed death ligand-1 expression and survival in urinary bladder cancer based on real-world data
por: Revesz, Janos, et al.
Publicado: (2023)

Alternative Splicing-Based Differences Between Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: Genes, Immune Microenvironment, and Survival Prognosis
por: Luo, Dingan, et al.
Publicado: (2021)

Association Between Programmed Death-Ligand 1 Expression and the Vascular Endothelial Growth Factor Pathway in Angiosarcoma
por: Bagaria, Sanjay P., et al.
Publicado: (2018)

Programmed Death Ligand 2 Gene Polymorphisms Are Associated With Lung Adenocarcinoma Risk in Female Never-Smokers
por: Liang, Sheng-Kai, et al.
Publicado: (2021)

The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer
por: Bronte, Giuseppe, et al.
Publicado: (2021)

Efficacy and Safety of Second-line Treatments in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: A Meta-analysis
por: An, Limin, et al.
Publicado: (2021)

Elevated DNA Polymerase Delta 1 Expression Correlates With Tumor Progression and Immunosuppressive Tumor Microenvironment in Hepatocellular Carcinoma
por: Zhao, Shuai, et al.
Publicado: (2021)

Positive Expression of Programmed Death Ligand 1 in Peritumoral Liver Tissue is Associated with Poor Survival after Curative Resection of Hepatocellular Carcinoma()
por: Dai, Xiaomeng, et al.
Publicado: (2017)

Safety and Activity of Programmed Cell Death 1 Versus Programmed Cell Death Ligand 1 Inhibitors for Platinum-Resistant Urothelial Cancer: A Meta-Analysis of Published Clinical Trials
por: Li, Zaishang, et al.
Publicado: (2021)

Correlation and Survival Analysis of Distant Metastasis Site and Prognosis in Patients With Hepatocellular Carcinoma
por: Zhan, Hao, et al.
Publicado: (2021)

The Clinical Significance of Soluble Programmed Cell Death-Ligand 1 (sPD-L1) in Patients With Gliomas
por: Liu, Shujun, et al.
Publicado: (2020)

p53 Expression, Programmed Death Ligand 1, and Risk Factors in Urinary Tract Small Cell Carcinoma
por: Golijanin, Borivoj, et al.
Publicado: (2021)

Identification and Validation of Tumor Stromal Immunotype in Patients With Hepatocellular Carcinoma
por: Li, Wei, et al.
Publicado: (2019)

Feasibility of hepatocellular carcinoma treatment based on the tumor microenvironment
por: Wang, Haiqiang, et al.
Publicado: (2022)

Long noncoding RNA TLNC1 promotes the growth and metastasis of liver cancer via inhibition of p53 signaling
por: Yuan, Kefei, et al.
Publicado: (2022)

MGL Ligand Expression Is Correlated to Lower Survival and Distant Metastasis in Cervical Squamous Cell and Adenosquamous Carcinoma
por: Sahasrabudhe, Neha M., et al.
Publicado: (2019)

The potential of soluble programmed death-ligand 1 (sPD-L1) as a diagnosis marker for colorectal cancer
por: Shao, Weifang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_il3q25j6otmq8t5tuaqo85hou7